Literature DB >> 9066001

The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation.

D Prasa1, L Svendsen, J Stürzebecher.   

Abstract

In a thrombin generation test with continuous registration of thrombin activity in plasma we studied the ability of a variety of thrombin inhibitors of different type and mechanism of action of influence the activity of thrombin after activation of the coagulation system. Depending on the inhibitor, the peak of thrombin activity is delayed and/or reduced. By blocking the active site of generated thrombin inhibitors cause a concentration dependent reduction of the thrombin peak and inhibit feed-back reactions of thrombin resulting in a delay of thrombin generation. Highly potent synthetic active-site directed inhibitors (Ki < or = 20 nM) reduce the thrombin activity formed in plasma after extrinsic or intrinsic activation with the same efficiency (IC50 0.1-0.6 microM) as hirudin. The delay and reduction of thrombin generation by inhibitors of the anion-binding exosite 1 of thrombin is only attributed to an inhibition of feed-back reactions of thrombin. For a 50% reduction of thrombin activity in plasma by this type of inhibitors relatively high concentrations were determined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066001

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Endurance training modifies exercise-induced activation of blood coagulation: RCT.

Authors:  Thomas Hilberg; Kathleen Menzel; Udo F Wehmeier
Journal:  Eur J Appl Physiol       Date:  2012-12-13       Impact factor: 3.078

2.  Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids.

Authors:  Brian L Henry; Jay N Thakkar; Erika J Martin; Donald F Brophy; Umesh R Desai
Journal:  Blood Coagul Fibrinolysis       Date:  2009-01       Impact factor: 1.276

3.  Blood coagulation and fibrinolysis in healthy, untrained subjects: effects of different exercise intensities controlled by individual anaerobic threshold.

Authors:  Kathleen Menzel; Thomas Hilberg
Journal:  Eur J Appl Physiol       Date:  2010-09-22       Impact factor: 3.078

Review 4.  A review of the clinical uses of ximelagatran in thrombosis syndromes.

Authors:  Elizabeth A Bergsrud; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

5.  Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.

Authors:  Michael Wolzt; Maria Wollbratt; Mia Svensson; Karin Wåhlander; Margaretha Grind; Ulf G Eriksson
Journal:  Eur J Clin Pharmacol       Date:  2003-09-04       Impact factor: 2.953

6.  Association of changes in D-dimer and other coagulation markers with changes in Marder score after treatment of acute venous thrombosis.

Authors:  Job Harenberg; Kirsten Merx; Ursula Hoffmann; Alexander R Tolle; Menno V Huisman
Journal:  J Thromb Thrombolysis       Date:  2002-08       Impact factor: 2.300

7.  Insight into Factors Influencing Wound Healing Using Phosphorylated Cellulose-Filled-Chitosan Nanocomposite Films.

Authors:  Marta Kędzierska; Sara Blilid; Katarzyna Miłowska; Joanna Kołodziejczyk-Czepas; Nadia Katir; Mohammed Lahcini; Abdelkrim El Kadib; Maria Bryszewska
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

8.  Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.

Authors:  Yves Decrem; Géraldine Rath; Virginie Blasioli; Philippe Cauchie; Séverine Robert; Jérôme Beaufays; Jean-Marie Frère; Olivier Feron; Jean-Michel Dogné; Chantal Dessy; Luc Vanhamme; Edmond Godfroid
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.